All In Biotech

BLA 017837 · Iso Tex

Megatope

Albumin Iodinated I-131 Serum · Injection

Last checked: Nov 20, 2026Latest source record: Aug 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1976

Feb 23, 1976

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 0 recruiting

FAERS reports

2

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 1, 2023.

INDICATIONS AND USAGE MEGATOPE is indicated in adults for use in determinations of total blood and plasma volumes.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 23, 1976 Original approval · Type 5 - New Formulation or New Manufacturer
5 products under this application
  • MEGATOPE · ALBUMIN IODINATED I-131 SERUM 20uCi/AMP · INJECTABLE, INJECTION · Discontinued
  • MEGATOPE · ALBUMIN IODINATED I-131 SERUM 2mCi/VIAL · INJECTABLE, INJECTION · Discontinued
  • MEGATOPE · ALBUMIN IODINATED I-131 SERUM 0.5mCi/VIAL · INJECTABLE, INJECTION · Prescription
  • MEGATOPE · ALBUMIN IODINATED I-131 SERUM 5uCi/AMP · INJECTABLE, INJECTION · Discontinued
  • MEGATOPE · ALBUMIN IODINATED I-131 SERUM 1mCi/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Albumin Iodinated I-131 Serum" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1
  • headache1
  • inappropriate schedule of product administration1
  • lacrimation increased1
  • nausea1
  • product dose omission issue1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20221
20231

Recalls

2 FDA enforcement reports for this application.

  • Apr 15, 2019 · Class II · Terminated

    Lack of Assurance of Sterility: environmental monitoring report exceeds limits, therefore sterility cannot be assured.

  • Mar 11, 2019 · Class II · Terminated

    Lack of Assurance of Sterility: preliminary environmental monitoring report exceeds limits, therefore sterility cannot be assured.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Iso Tex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.